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Adipocyte fatty acid binding protein (aFABP, aP2) is a 14.6 kDa cytosolic protein located in adipocytes and macrophages and assists in 
the intracellular transport of fatty acids. It is one of a class of fatty acid binding proteins (FABPs) that are found predominately in the 
liver, heart, intestine and connective tissues.  Hotamisligal et al. have reported that aFABP-deficient mice, when placed on a high fat diet 
(40% of caloric intake as fat), were significantly protected from hyperinsulinemia and insulin resistance compared to the wild type.  
Additional genetic experiments have been reported in which aFABP null mice have been crossed with ob/ob and in another instance 
apoE-/- mice.  The aFABP-deficient ob/ob mice were more insulin sensitive when compared to ob/ob controls as demonstrated measuring 
by circulating glucose and insulin levels. 
. 
   Based on these genetic knock-out models, we pursued the development of inhibitors of 
aFABP for their therapeutic potential in the treatment of diabetes.  Herein we disclose the synthesis of two azole inhibitors of P2 and the 
methods used to prepare them 
Introduction 
With the spread of Western lifestyles, the prevalence of 
type 2 diabetes is rising.  In the United State it is estimated that 
nearly 21 million children and adults (7.0% of the population) 
have diabetes. Of this number only 15 million are currently 
diagnosed.  Alarmingly, it is also estimated that there are 
potentially 54 million people who are currently “pre-diabetic”. 
This is a situation where glucose is only partially controlled.  If 
the situation is left unmanaged it is anticipated that these 
individuals will ultimately exhibit the disease. Taken together, 
there are 1.5 million new cases of diabetes being diagnosed in 
people aged 20 years or older (2005 data) within the United 
States each year.  The expectation is that these numbers are likely 
to greatly increase in the near future.
Diabetes is characterized by hyperglycemia and 
disturbances of carbohydrates, lipid and protein metabolism. As 
these metabolic disturbances become “chronic,” a wide variety of 
medical problems present themselves. Foremost among them 
these are heart disease and stroke accounting for 65% of deaths in 
people with diabetes.  In addition, a high percentage of diabetics 
are afflicted with hypertension. Diabetic complications are not 
limited to cardiovascular concerns.  Diabetes also has a 
detrimental impact on the retina, kidney and nervous systems.  
The disease becomes the basis for 24,000 new cases of blindness 
annually, nearly half of new cases of kidney failure, and a major 
percentage of lower limb amputations;
1 
2 the total cost of the 
disease is currently estimated at over 150 billion dollars in the 
United States annually.1
Current diabetes treatment strategies include: reducing 
insulin resistance using glitazones,
   
3 supplementing insulin 
supplies with exogenous insulin,4 increasing insulin secretion 
with sulfonyl ureas,5 and reducing hepatic glucose production 
with biguanides.6  Recently, treatment strategies using  DPP-IV 
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  have also emerged. Of the 
aforementioned list, the mechanisms of action generally focus on 
treating type 2 diabetes predominately from the glucose/insulin 
axis.  However, there is currently no chemical agent that 
addresses diabetes via altered energy homeostasis from the fatty 
acid vantage point.  By altering the modulation of energy stores 
along the fatty acid axis an impact on circulating glucose levels 
would be expected.  This strategy then provides a new basis for 
therapy. 
Figure 1:Potent Inhibitors of aP2 
A promising new diabetes target for investigation is the 
inhibition of aP2.8  aP2 is one of a family of homologous 
intracellular fatty acid binding proteins that is involved in the 
regulation of fatty acid trafficking. aP2 is found in adipocytes and 
mediates fatty acid fluxes in adipose tissue.9 Hotamisligal et al. 
have reported that aFABP deficient mice, when placed on a high 
fat diet (40% of caloric intake as fat), were significantly protected 
from hyperinsulinemia and insulin resistance compared to the 
wild type.10 Additional genetic experiments have been reported in 
which aFABP null mice have been crossed with ob/ob mice.  The 
aFABP deficient ob/ob mice were more insulin sensitive when 
compared to ob/ob controls as demonstrated measuring by 
circulating glucose and insulin levels.11 Supported by these 
genetic knock-out models, aP2 inhibition presents itself as an 
perfect target for the treatment of diabetes.9  Moreover, workers at 
Harvard and Bristol-Myers Squibb recently reported successful 
intervention with an aP2 inhibitor against a wide variety of 
diabetes markers including fasting and parandial glucose levels in 
the ob/ob mouse.
There are several reports of aP2 inhibitors in the 
literature;
12 
11 these papers typically reveal binding affinities to aP2 
and very limited chemical synthetic procedures.  Our goal was to 
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prepare two known potent inhibitors of aP212
 
 (Figure 1) and 
disclose needed experimental details to provide access in 
determining if these agents would serve as forerunners of a new 
therapeutic class of anti-diabetic agents. For this reason the 
preparation of the two compounds below was undertaken.  They 
both have high binding affinity to aP2.  The first compound was 
prepared according to the methods in Scheme 1.  The second 
compound was prepared as seen in Scheme 2.  
Chemistry: 
 In Scheme 1, benzoin (3) was reacted with 2-bromo-
benzoic acid under standard conditions to give benzoin 2-bromo-
benzoate. The ester was reacted without purification and 
immediately treated with ammonium acetate in acetic acid to 
generate oxazole 4 (45% overall).  Compound 4 smoothly 
underwent palladium catalyzed cross coupling with 3-methoxy 
phenyl boronic acid in 75% isolated yield.  Deprotection of the 
methyl group was achieved with BBr3 to provide hydroxyl-
biphenyl 6.  For this conversion, maintaining the reaction 
temperature below 0 °C proved to be critical in the successful 
transformation of the ether to the alcohol. Warmer temperatures 
and prolonged reaction times generated multiple side products. 
Isolated yields of the alcohol were around 55%. The final two 
steps in generating the target inhibitor required coupling of the 



































followed by hydrolysis of the ester (KOH in alcohol 50%) to 
provide the target molecule (1).  Isolation of the salt was 
accomplished with the agency of SP207 gel column 
chromatography.   
 
Scheme 1: a. (COCl)2, 2-bromobenzoic acid; b.NH4OAc, HOAc, Δ; c. 
methoxyphenyl boronic acid, Pd(PPh3)4, Na2CO3; d. BBr3, -5 °C; e. 
ethyl bromoacetate, K2CO3
Compound 2 was prepared as outlined in Scheme 2.  2-
Bromo-benzaldelhyde was reacted with diketone 8 to form an 
imidazole.  The imidazole ring was then alkylated with ethyl 
iodide in the presence of K
; f. NaOH.   
2CO3 to give 9 (65% overall).  
Compound 9 was reacted with palladium (0) tetrakistriphenyl-
phosphine under Suzuki conditions generating biphenyl 10. The 
yields of the reaction tended to vary but averaged around 70%.  
The methyl ether in 10 was deprotected with boron tribromide 
with reaction temperatures below 0˚C to liber ate phenol 11 
(yields 35%-50%).  The target molecule 2 was prepared by 
K2CO3
                   
/DMF and ethyl bromoacetate coupling followed by base 
hydrolysis.  Overall conversions were around 35% for the last 































Scheme 2: a. NH4OAc, HOAc, 2-bromo-benzaldelhye; b. ethyl iodide, 
K2CO3; c. methoxyphenyl boronic acid, Pd(PPh3)4, Na2CO3; d. BBr3, -5 
°C; e. ethyl bromoacetate, K2CO3
Materials and Methods 
; f. NaOH 
Reagents were purchased from Aldrich Chemical (P.O. 
Box 2060 Milwaukee, WI 53201) and used without further 
purification.  All column chromatography was carried out using 
ACROS silica gel 0.20 -0.50 mm, pore diameter – 4 nm. TLC 
was carried out on Merk Silica Gel Plates with a UV binder. 
Typical visualization was accomplished by UV, I2 or KMnO4 
staining.   1H NMR was carried out on an Anasazi EFT-60 MHz 
Spectrometer referenced to TMS.  HPLC was carried out using 
Waters 1525 HPLC. Column: Waters X-Terra Phenyl: pore 5um, 
length 4.6X150mm. UV detection at 220 and 245 nm. A linear 
gradient from 100% solvent A to 100% solvent B was run from 
time 0 min. to time 16 min. Solvent A: (water:methanol:acetic 
acid; 9/1/.025), Solvent B (water:methanol:acetic acid; 1/9/.025). 
SP207 gel was purchased from Sorbent Technologies (2377 John 
Glen Dr. Atlanta, GA 30341) and used after washing with 
solutions of NaOH, HCl, water, methanol, and acetone.  The resin 
was stored over a solution of very dilute NaHCO3
 
:methanol 
solution (95:5 v/v). 
A solution of 2-bromobenzoic acid (5.00 g, 24.77 
mmol) and dichloromethane (50 mL) was treated with oxalyl 
Preparation of 2-(2-bromophenyl)-4,5-diphenyl-1,3-oxazole 
(3). 
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chloride (3.81g, 30.00 mmol) and dimethyl formamide (5 drops).  
The reaction mixture was stirred until all gas evolution has 
stopped (0.5 h).  The mixture was stripped on a rotoevaporator 
and the remaining acid chloride diluted with dichloromethane 
(100 mL).  The slight yellow solution was mixed with benzoin 
(4.64 g, 22.00 mmol) and triethylamine (7.50, 75.00 mmol). The 
mixture was stirred overnight and diluted with water.  The layers 
were separated and the dichloromethane fraction washed with 
Na2CO3 solution and then KHSO4.  The organics were dried 
over MgSO4
 
 and concentrated to give the ketoester as a colorless 
oil.  
The crude ester (3.60 g, @ 9.4 mmol) from above was 
mixed with ammonium acetate (3.60 g, 47 mmol) and acetic acid 
(35 mL).  The mixture was brought to reflux for 4 h and cooled to 
ambient temperature.  The organics were diluted with ethyl 
acetate and water.  The layers equilibrated and separated.  The 
organic fraction was washed with water, NaHCO3, brine, dried 
(MgSO4) and concentrated to give yellow oil.  The oil was 
recrystalized from a small volume of hot methanol to give the 
desired oxazole (2.20 g, 61%).  TLC (1:3 ethyl acetate/hexane) 
Rf = 0.4; 1H NMR (CDCl3
 
) δ 8.20 -6.90 (m, 14 H) ppm.   
Nitrogen was bubbled through a solution of 3 (0.29 g, 




2CO3 (0.7 mL, 2M) in toluene (3 mL) and 
ethanol  (0.85mL) for about 10 min.  Tetrakis 
(triphenylphosphine) palladium (0) (50 mg) was added and the 
reaction was heated in an oil bath set at 77˚C for 14 h. The 
mixture was cooled and diluted with ethyl acetate (25 mL) and 
the organics were washed with water, NaHCO3, dried and 
concentrated.  The remainder was purified on silica gel column 
chromatography with 1:5 ethyl acetate in hexanes as a mobile 
phase. The procedure provided 0.27 g (85%) of the title 
compound. TLC (1:3 ethyl acetate/hexane) Rf = 0.7; 1H NMR 
(CDCl3
 
) δ 8.20 -6.90 (m, 18 H), 3.50 (s, 3H) ppm. 
To a solution of 4 (0.25 g, 0.62 mmol) in anhydrous 
dichloromethane at -10˚C was added boron tribromide in 
dichloromethane dropwise (2M, 0.65 mL).  The reaction was 
stirred at -5˚C for 1 h and quenched with aqueous NaHCO
2'-(4,5-diphenyl-1,3-oxazol-2-yl)biphenyl-3-ol (5). 
3 
solution and the pH adjusted to 6 with dilute HCl.   The mixture 
was diluted with ethyl acetate and the organics separated from the 
aqueous fraction.  The organics were washed with brine, dried 
over MgSO4 and concentrated.  The remainder was purified on 
silica gel column chromatography with dichloromethane and then 
10% ethyl acetate/dichloromethane to give the title compound 
(0.10 g, 55%). TLC (1:3 ethyl acetate/hexane) Rf = 0.3; 1H NMR 
(CDCl3
 
) δ 8.20 -7.00 (m, 18 H), 1.90 (s broad, 1H) ppm. 




2CO3 (0.055 g, 0.04 mmol), ethyl bromoacetate (0.038 g, 0.02 
mmol) and compound 5 (0.080 g; 0.20 mmol).  The biphasic 
mixture was stirred overnight and diluted sequentially with ethyl 
acetate 15 mL and water 15 mL.  The layers were separated and 
the organic fraction was washed with water, dried over Na2SO4 
and concentrated.  The remainder was purified by silica gel 
column chromatorgray with ethyl acetate and hexanes as a mobile 
phase.  A gradient elution from hexane to 25% ethyl acetate in 
hexane provided the title compound. (0.80 g, 50%-85%). TLC 
(1:3 ethyl acetate/hexane) Rf = 0.5; 1H NMR (CDCl3
 
) δ 7.90 -
6.80 (m, 18 H), 4.60 (s, 2H), 4.20 (q, 2H, J=7.5 Hz), 1.60 (t, 3H, 
J=7.5 Hz) ppm. 
A 25 mL RB flask was charged with ethanol (7 mL), 
NaOH (0.4 g, 10 mmol), compound 6 (0.80 g, 0.16 mmol) and 1 
mL of water.  The mixture was heated to reflux for 6 h and 
cooled to room temperature.  The mixture was concentrated and 
purified on SP207 gel using a step gradient with 100 mL volumes 
starting with water; 10% methanol in water; 20% methanol in 
water; 30% methanol in water; 50% methanol in water; 75 % 
methanol in water; 90% methanol in water;  and methanol  to 
give 0.18 g of final product. TLC (1:3 ethyl acetate/hexane) R
[[2'-(4,5-diphenyl-1,3-oxazol-2-yl)biphenyl-3-yl]oxy]acetic 
acid, sodium form (1) Inhibitor 1. 
f = 
0.05; HPLC: Retention Time: 15.4 min.  1H NMR (CD3
 
OD) δ 
7.90 -6.80 (m, 18 H), 4.50 (s, 2H) ppm. 
Benzil (8) (4.20 g, @ 20.0 mmol) was mixed with 
ammonium acetate (14.40 g, 188 mmol), acetic acid (45 mL) and 
2-bromo-benzaldehyde (3.70 g, 20.0 mmol).  The mixture was 
brought to reflux for 14 h and cooled to ambient temperature.  
The organics were diluted with a large volume of water and a 
white solid formed.  The solid was collected by filtration and 
dried overnight.  After standing overnight the material maintained 
a strong acetic acid odor. The solid was then triturated with water 
and filtered three times to remove any acetic acid and/or 
ammonium salts. The solid collected provided the title compound 
(6.20 g, 83%). TLC (1:3 ethyl acetate/hexane) R
2-(2-bromophenyl)-4,5-diphenyl-1H-imidazole (8a). 
f = 0.5; 1H NMR 
(CDCl3
 
) δ 8.20-7.20 (m, 14 H), 1.80 (s broad, 1H) ppm.   
To a mixture of 8a (2.5 g; 6.70 mmol), K
2-(2-bromophenyl)-1-ethyl-4,5-diphenyl-1H-imidazole (9). 
2CO3 (1.33 g; 
10.00 mmol) and DMF (20 mL) was added ethyl iodide (1.40 g; 
8.80 mmol).  The mixture was stirred overnight and diluted with 
water.  After vigorous stirring a white solid was formed.  The 
solid was collected by filtration and dried overnight.  The 
material was triturated with water two times and the resulting 
solid collected by filtration.  The solid collected provided the title 
compound (2.19 g, 82%). TLC (1:3 ethyl acetate/hexane) Rf = 
0.6; 1H NMR (CDCl3
 
) δ 7.80 -7.00 (m, 14 H), 3.75 (q, 2H, 
J=11.5 Hz), 0.95 (t, 3H, J=11.5 Hz) ppm.   
1-ethyl-2-(3'-methoxybiphenyl-2-yl)-4,5-diphenyl-1H-
imidazole (10
  Nitrogen was bubbled through a solution of 9 (0.35 g, 
0.81 mmol), 3-methoxy-phenyl boronic acid (0.15 g, 0.98 mmol) 
and aqueous Na
). 
2CO3 (0.7 mL, 2M) in toluene (3 mL) and 
ethanol (0.85 mL) for about 10 min.  Tetrakis 
(triphenylphosphine) palladium (0) (50 mg) was added and the 
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reaction was heated in an oil bath set at 77˚C for 14 h. The 
mixture was cooled and diluted with ethyl acetate (25 mL) and 
the organics were washed with water, NaHCO3, dried and 
concentrated.  The remainder was purified on silica gel column 
chromatography with 1:5 ethyl acetate in hexanes as a mobile 
phase. The procedure provided (0.23 g, 61%) of the title 
compound. TLC (1:3 ethyl acetate/hexane) Rf = 0.8; 1H NMR 
(CDCl3
 
) δ 7.80-6.90 (m, 18 H), 3.60 (s, 2H), 3.20 (q, 2H, J=8.5 
Hz), 0.60 (t, 3H, J=8.5 Hz) ppm.   
1-ethyl-2-(3'-hydroxybiphenyl-2-yl)-4,5-diphenyl-1H-
imidazole (11
To a solution of 10 (0.25 g, 0.62 mmol) in anhydrous 
dichloromethane at -10 ˚C was added boron tribromide in 
dichloromethane drop wise (2M, 0.65 mL).  The reaction was 
stirred at -10˚C for 90 min. and quenched with methanol (2 mL).  
The mixture was stirred for 1 h at RT. and the pH adjusted to 7 
with dilute NaHCO
). 
3 solution.   The mixture was diluted with 
ethyl acetate and the organics separated from the aqueous 
fraction.  The organics were washed with brine, dried over 
MgSO4 and concentrated.  The remainder was purified on silica 
gel column chromatography with dichloromethane and then 10% 
ethyl acetate/dichloromethane to give the title compound (0.13 g, 
50%). Rf = 0.3; 1H NMR (CDCl3
 
) δ 7.80-6.90 (m, 18 H), 3.30 (q, 
2H, J=8.5 Hz), 2.10 (s broad, 1H), 0.70 (t, 3H, J=8.5 Hz) ppm. 




2CO3 (0.055 g, 0.04 mmol), ethyl bromoacetate (0.038 g, 0.02 
mmol) and compound 11 (0.10 g; 0.22 mmol).  The biphasic 
mixture was stirred overnight and was diluted sequentially with 
ethyl acetate 15 mL and water 15 mL.  The layers were separated 
and the organic fraction was washed with water, dried over 
Na2SO4 and concentrated.  The remainder was purified by silica 
gel column chromatography with ethyl acetate and hexanes as a 
mobile phase.  A gradient elution from hexane to 25% ethyl 
acetate in hexane provided the title compound. (0.80 g, 70%). Rf 
= 0.6; 1H NMR (CDCl3
 
) δ 7.90-6.90 (m, 18 H), 4.60 (s, 2H), 4.20 
(q, 2H, J=7 Hz) 3.30 (q, 2H, J=9 Hz), 1.70 (t, 3H, J=7 Hz), 0.60 
(t, 3H, J=9 Hz) ppm. 
A 25 mL RB flask was charged with ethanol (7 mL), 
NaOH (0.4 g, 10 mmol), compound 12 (0.10 g, 0.16 mmol) and 1 
mL of water.  The mixture was heated to reflux for 1 h and 
cooled to room temperature.  The mixture was concentrated and 
purified on SP207 gel using a step gradient with 100 mL volumes 
starting with water; 10% methanol in water; 20% methanol in 
water; 30% methanol in water; 50% methanol in water;  methanol 
in water; 90% methanol in water; methanol  to give 0.09 g of 
final product. R
[[1-ethyl-2-4,5-diphenyl-1H-imidazole]biphenyl-3-yl]oxy] 
acetic acid, sodium form (2) Inhibitor 2. 
f = 0.05; HPLC: Retention Time: 15.0 min. 1H 
NMR (CD3
 
OD) δ 7.90-6.90 (m, 18 H), 4.60 (s, 2H), 3.30 (q, 2H, 
J=9 Hz), 0.60 (t, 3H, J=9 Hz) ppm. 
Results and Conclusion:  
 Herein we have described the preparation of two 
inhibitors of aP2.  The methods disclosed are suitable to generate 
milligram to gram quantities of these inhibitors.  All of the 
reactions are robust and give fair to excellent yields of products.  
A key component to the isolation of the final salts is the 
utilization of SP-207 resin.  This resin provides a convenient 
system for preparative reverse phase isolation of organic salts.  
Herein the isolation of these fatty acid salts was demonstrated. 
  The synthesis of these potent inhibitors has been 
accomplished and it is intended that further utilization of these 
unique compounds will enhance our understanding of diabetes 
and new treatments for the disease. This rationale is consistent 
with the information reported by Hotamisligil utilizing the ob/ob 
mouse model.  These animals suffer from severe obesity and very 
high glucose levels.  In this animal model, the aP2 inhibitors not 
only reduced glucose levels but also demonstrated increased 
sensitivity to insulin.  The Harvard results suggest that new 
diabetic treatments could be forthcoming by interference of the 
fatty acid trafficking pathway.  
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